TY  - CONF
AU  - Estrada, Vicente
AU  - Monge, Susana
AU  - Gómez-Garre, Dulcenombre
AU  - Sobrino, Paz
AU  - Berenguer, Juan
AU  - Bernardino, José Ignacio
AU  - Santos, Jesús
AU  - Moreno Zamora, Ana
AU  - Martínez, Esteban
AU  - Blanco, Jose Ramón
PY  - 2014
UR  - http://hdl.handle.net/10668/1842
T2  - Journal of the international AIDS society
AB  - INTRODUCTIONChronic low-grade inflammation and immune activation may persist in HIV patients despite effective antiretroviral therapy (ART). These abnormalities are associated with increased oxidative stress (OS). Bilirubin (BR) may have a beneficial...
LA  - en
PB  - International AIDS Society
KW  - Infecciones por VIH
KW  - Estrés oxidativo
KW  - Benzoxazinas
KW  - Fármacos anti-VIH
KW  - Inhibidores de la proteasa VIH
KW  - Oligopéptidos
KW  - Estudio comparativo
KW  - Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
KW  - Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Oxidative Stress
KW  - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazines
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agents
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors
KW  - Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Oligopeptides
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
KW  - Medical Subject Headings::Publication Characteristics::Study Characteristics::Comparative Study
TI  - Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy.
TY  - conference presentation
ER  -